{
    "clinical_study": {
        "@rank": "166719", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.   Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of\n      eclamptic seizures in patients with severe preeclampsia."
        }, 
        "brief_title": "Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia", 
        "completion_date": "August 2000", 
        "condition": "Pre-Eclampsia", 
        "condition_browse": {
            "mesh_term": [
                "Eclampsia", 
                "Pre-Eclampsia"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, international, multicenter study.  Patients are\n      randomized to receive either nimodipine or magnesium sulfate.\n\n      Arm I: Patients receive nimodipine by mouth every 4 hours.  Treatment is continued until 24\n      hours post-partum.\n\n      Arm II: Patients receive a loading dose of magnesium sulfate IV for 20 minutes, followed by\n      continuous infusion of magnesium sulfate.  Treatment is continued until 24 hours\n      post-partum."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Histologically diagnosed severe preeclampsia at risk for eclamptic convulsions with\n             the following criteria:\n\n          -  Blood pressure greater than 160/110 mmHg OR Mean arterial pressure of 126 mmHg\n\n          -  Proteinuria greater than 5 g/24 hr\n\n          -  Epigastric pain OR Right upper quadrant pain AST/ALT greater than 70 U/L\n\n          -  Severe headache and/or scotomata\n\n          -  Thrombocytopenia as evidenced by: Platelet count less than 100,000/mm3 Disseminated\n             intravascular coagulation Microangiopathic hemolytic anemia Oliguria (less than 400\n             mL/day or 30 mL/hr)\n\n          -  Pulmonary edema\n\n        --Prior/Concurrent Therapy--\n\n          -  No prior/concurrent magnesium sulfate or dihydropyridine agents\n\n          -  No other concurrent antiseizure medications\n\n        --Patient Characteristics--\n\n          -  Age: Not specified\n\n          -  Performance status: Not specified\n\n          -  Hematopoietic: See Disease Characteristics\n\n          -  Hepatic: See Disease Characteristics\n\n          -  Renal: No severe renal failure See Disease Characteristics\n\n          -  Cardiovascular: No history of angina or myocardial infarction No cardiac dysfunction\n             No history or sign of congestive cardiac failure No arrhythmia with ventricular rate\n             less than 60 bpm See Disease Characteristics\n\n          -  Pulmonary: See Disease Characteristics\n\n        --Other:--\n\n          -  No severe mental or physical disorder that may affect therapy\n\n          -  Not allergic to drugs with chemical structure similar to nimodipine or magnesium\n             sulfate\n\n          -  No evidence of fetal distress or fetal anomalies"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "2000", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004399", 
            "org_study_id": "199/13249", 
            "secondary_id": [
                "UU-FDR001061", 
                "BCM-FDR001061"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "magnesium sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "nimodipine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Magnesium Sulfate", 
                "Nimodipine"
            ]
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "hypertensive disorder", 
            "pre-eclampsia", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Utah", 
            "last_name": "Michael Anthony Belfort", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004399"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Utah", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 1995", 
        "study_design": "Allocation: Randomized, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2001"
    }, 
    "geocoordinates": {}
}